118 related articles for article (PubMed ID: 31335489)
1. Comparison of PAX8 Expression in Breast Carcinoma Using MRQ50 and BC12 Monoclonal Antibodies.
Singh K; Hanley LC; Sung CJ; Quddus MR
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):558-561. PubMed ID: 31335489
[TBL] [Abstract][Full Text] [Related]
2. PAX8 mouse monoclonal antibody [BC12] recognizes a restricted epitope and is highly sensitive in renal cell and ovarian cancers but does not cross-react with b cells and tumors of pancreatic origin.
Tacha D; Qi W; Zhou D; Bremer R; Cheng L
Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):59-63. PubMed ID: 22595948
[TBL] [Abstract][Full Text] [Related]
3. Unexpected PAX8 Immunoreactivity in Metastatic High-grade Breast Cancer.
Kilgore MR; Bosch DE; Adamson KH; Swanson PE; Dintzis SM; Rendi MH
Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):637-643. PubMed ID: 30358609
[TBL] [Abstract][Full Text] [Related]
4. PAX8 Expression in Breast Cancer.
Lu S; Yakirevich E; Hart J; Wang L; Wang Y
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):293-298. PubMed ID: 33208672
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive analysis of PAX8 expression in human epithelial tumors.
Laury AR; Perets R; Piao H; Krane JF; Barletta JA; French C; Chirieac LR; Lis R; Loda M; Hornick JL; Drapkin R; Hirsch MS
Am J Surg Pathol; 2011 Jun; 35(6):816-26. PubMed ID: 21552115
[TBL] [Abstract][Full Text] [Related]
6. The Diagnostic Utility of PAX8 for Neuroendocrine Tumors: An Immunohistochemical Reappraisal.
Liau JY; Tsai JH; Jeng YM; Kuo KT; Huang HY; Liang CW; Yang CY
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):57-63. PubMed ID: 25710581
[TBL] [Abstract][Full Text] [Related]
7. Polyclonal PAX8 expression in carcinomas of the biliary tract - Frequent non-specific staining represents a potential diagnostic pitfall.
Zong Y; Xiong Y; Dresser K; Yang M; Bledsoe JR
Ann Diagn Pathol; 2021 Aug; 53():151762. PubMed ID: 34102541
[TBL] [Abstract][Full Text] [Related]
8. Do You Know the Details of Your PAX8 Antibody? Monoclonal PAX8 (MRQ-50) Is Not Expressed in a Series of 45 Medullary Thyroid Carcinomas.
Gucer H; Caliskan S; Kefeli M; Mete O
Endocr Pathol; 2020 Mar; 31(1):33-38. PubMed ID: 31912298
[TBL] [Abstract][Full Text] [Related]
9. Utility of monoclonal PAX8 antibody for distinguishing intrathyroid thymic carcinoma from follicular cell-derived thyroid carcinoma.
Suzuki A; Hirokawa M; Takada N; Higuchi M; Tanaka A; Hayashi T; Kuma S; Miyauchi A
Endocr J; 2018 Dec; 65(12):1171-1175. PubMed ID: 30210064
[TBL] [Abstract][Full Text] [Related]
10. A novel monoclonal antibody (7B10) with differential reactivity between human mammary carcinoma and normal breast.
Pancino G; Charpin C; Calvo F; Guillemin MC; Roseto A
Cancer Res; 1987 Aug; 47(16):4444-52. PubMed ID: 3607774
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma.
Bhargava R; Lal P; Chen B
Diagn Mol Pathol; 2004 Dec; 13(4):213-6. PubMed ID: 15538111
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Paired Box 8 (PAX8)-expressing Metastatic Breast Carcinoma.
Kim SW; Kim HS; Na K
Anticancer Res; 2020 Oct; 40(10):5925-5932. PubMed ID: 32988924
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors.
Lorenzo PI; Jimenez Moreno CM; Delgado I; Cobo-Vuilleumier N; Meier R; Gomez-Izquierdo L; Berney T; Garcia-Carbonero R; Rojas A; Gauthier BR
Histochem Cell Biol; 2011 Nov; 136(5):595-607. PubMed ID: 21932072
[TBL] [Abstract][Full Text] [Related]
14. Expression of wild-type estrogen receptor beta protein in human breast cancer: specific correlation with HER2/neu overexpression.
Umekita Y; Souda M; Ohi Y; Sagara Y; Rai Y; Takahama T; Yoshida H
Pathol Int; 2006 Aug; 56(8):423-7. PubMed ID: 16872435
[TBL] [Abstract][Full Text] [Related]
15. Unusual staining of immunohistochemical markers PAX8 and CDX2 in breast carcinoma: a potential diagnostic pitfall.
Shen T; Zhao J; Zhao M; Taggart MW; Ramalingam P; Gong Y; Wu Y; Liu H; Zhang J; Resetkova E; Wang WL; Ding Q; Huo L; Yoon E
Hum Pathol; 2022 Jul; 125():35-47. PubMed ID: 35417734
[TBL] [Abstract][Full Text] [Related]
16. Comparison of different antibodies for detection of progesterone receptor in breast cancer.
Press M; Spaulding B; Groshen S; Kaminsky D; Hagerty M; Sherman L; Christensen K; Edwards DP
Steroids; 2002 Aug; 67(9):799-813. PubMed ID: 12123792
[TBL] [Abstract][Full Text] [Related]
17. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas.
Nonaka D; Chiriboga L; Soslow RA
Am J Surg Pathol; 2008 Oct; 32(10):1566-71. PubMed ID: 18724243
[TBL] [Abstract][Full Text] [Related]
18. NY-BR-1 and PAX8 immunoreactivity in breast, gynecologic tract, and other CK7+ carcinomas: potential use for determining site of origin.
Woodard AH; Yu J; Dabbs DJ; Beriwal S; Florea AV; Elishaev E; Davison JM; Krasinskas AM; Bhargava R
Am J Clin Pathol; 2011 Sep; 136(3):428-35. PubMed ID: 21846919
[TBL] [Abstract][Full Text] [Related]
19. PAX8 expression in anaplastic thyroid carcinoma is less than those reported in early studies: a multi-institutional study of 182 cases using the monoclonal antibody MRQ-50.
Lai WA; Hang JF; Liu CY; Bai Y; Liu Z; Gu H; Hong S; Pyo JY; Jung CK; Kakudo K; Bychkov A
Virchows Arch; 2020 Mar; 476(3):431-437. PubMed ID: 31732814
[TBL] [Abstract][Full Text] [Related]
20. Analytical and clinical performance of progesterone receptor antibodies in breast cancer.
Calhoun BC; Mosteller B; Warren D; Smith M; Jordi Rowe J; Lanigan CP; Mrazeck KC; Walker E; Newell AH; Jones R
Ann Diagn Pathol; 2018 Aug; 35():21-26. PubMed ID: 29758480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
